Cytokinetics Net Worth
Cytokinetics Net Worth Breakdown | CYTK |
Cytokinetics Net Worth Analysis
Cytokinetics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cytokinetics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cytokinetics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cytokinetics' net worth analysis. One common approach is to calculate Cytokinetics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cytokinetics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cytokinetics' net worth. This approach calculates the present value of Cytokinetics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cytokinetics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cytokinetics' net worth. This involves comparing Cytokinetics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cytokinetics' net worth relative to its peers.
Enterprise Value |
|
To determine if Cytokinetics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cytokinetics' net worth research are outlined below:
| Cytokinetics generated a negative expected return over the last 90 days | |
| Cytokinetics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 18.47 M. Net Loss for the year was (589.53 M) with loss before overhead, payroll, taxes, and interest of (320.93 M). | |
| Cytokinetics currently holds about 586.03 M in cash with (395.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22. | |
| Cytokinetics has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Disposition of 20900 shares by Andrew Callos of Cytokinetics at 45.14 subject to Rule 16b-3 |
Cytokinetics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cytokinetics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cytokinetics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Cytokinetics Target Price Consensus
Cytokinetics target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Cytokinetics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 18 | Strong Buy |
Most Cytokinetics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Cytokinetics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Cytokinetics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCytokinetics Target Price Projection
Cytokinetics' current and average target prices are 43.28 and 81.71, respectively. The current price of Cytokinetics is the price at which Cytokinetics is currently trading. On the other hand, Cytokinetics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Cytokinetics Market Quote on 19th of March 2025
Target Price
Analyst Consensus On Cytokinetics Target Price
Know Cytokinetics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cytokinetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cytokinetics backward and forwards among themselves. Cytokinetics' institutional investor refers to the entity that pools money to purchase Cytokinetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Polar Capital Holdings Plc | 2024-12-31 | 2.2 M | Marshall Wace Asset Management Ltd | 2024-12-31 | 2.2 M | Boxer Capital Llc | 2024-09-30 | 2.1 M | Pictet Asset Manangement Sa | 2024-12-31 | 1.9 M | Jpmorgan Chase & Co | 2024-12-31 | 1.6 M | Alliancebernstein L.p. | 2024-12-31 | 1.6 M | Orbimed Advisors, Llc | 2024-12-31 | 1.6 M | Northern Trust Corp | 2024-12-31 | 1.5 M | Citadel Advisors Llc | 2024-12-31 | 1.4 M | Blackrock Inc | 2024-12-31 | 15.5 M | Vanguard Group Inc | 2024-12-31 | 11.9 M |
Follow Cytokinetics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.32 B.Market Cap |
|
Project Cytokinetics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.44) | (0.46) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | 4.35 | 4.57 |
When accessing Cytokinetics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cytokinetics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cytokinetics' profitability and make more informed investment decisions.
Evaluate Cytokinetics' management efficiency
Cytokinetics has return on total asset (ROA) of (0.3011) % which means that it has lost $0.3011 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7215) %, meaning that it created substantial loss on money invested by shareholders. Cytokinetics' management efficiency ratios could be used to measure how well Cytokinetics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 4.57 this year, although the value of Return On Tangible Assets will most likely fall to (0.44). At this time, Cytokinetics' Liabilities And Stockholders Equity is quite stable compared to the past year. Non Current Liabilities Total is expected to rise to about 1.4 B this year, although the value of Non Current Liabilities Other will most likely fall to about 374 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.21) | (1.27) | |
| Tangible Book Value Per Share | (1.21) | (1.27) | |
| Enterprise Value Over EBITDA | (11.89) | (11.30) | |
| Price Book Value Ratio | (38.91) | (36.97) | |
| Enterprise Value Multiple | (11.89) | (11.30) | |
| Price Fair Value | (38.91) | (36.97) | |
| Enterprise Value | 318.6 M | 334.5 M |
Understanding the operational decisions made by Cytokinetics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 268.7756 | Revenue | Quarterly Revenue Growth 9.124 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cytokinetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cytokinetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cytokinetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cytokinetics Corporate Filings
F4 | 18th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 10th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 12th of February 2025 Other Reports | ViewVerify |
Cytokinetics Earnings Estimation Breakdown
The calculation of Cytokinetics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Cytokinetics is estimated to be -1.3615 with the future projection ranging from a low of -1.59 to a high of -1.17. Please be aware that this consensus of annual earnings estimates for Cytokinetics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.59 Lowest | Expected EPS | -1.17 Highest |
Cytokinetics Earnings Projection Consensus
Suppose the current estimates of Cytokinetics' value are higher than the current market price of the Cytokinetics stock. In this case, investors may conclude that Cytokinetics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Cytokinetics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 21 | 78.18% | -1.26 | -1.3615 | -5.26 |
Cytokinetics Earnings per Share Projection vs Actual
Actual Earning per Share of Cytokinetics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Cytokinetics predict the company's earnings will be in the future. The higher the earnings per share of Cytokinetics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Cytokinetics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Cytokinetics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Cytokinetics should always be considered in relation to other companies to make a more educated investment decision.Cytokinetics Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Cytokinetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-25 | 2024-12-31 | -1.174 | -1.26 | -0.086 | 7 | ||
2024-11-06 | 2024-09-30 | -1.25 | -1.36 | -0.11 | 8 | ||
2024-08-08 | 2024-06-30 | -1.06 | -1.31 | -0.25 | 23 | ||
2024-05-08 | 2024-03-31 | -1.14 | -1.33 | -0.19 | 16 | ||
2024-02-27 | 2023-12-31 | -0.97 | -1.38 | -0.41 | 42 | ||
2023-11-02 | 2023-09-30 | -0.74 | -1.35 | -0.61 | 82 | ||
2023-08-03 | 2023-06-30 | -1.15 | -1.34 | -0.19 | 16 | ||
2023-05-04 | 2023-03-31 | -1.2 | -1.38 | -0.18 | 15 | ||
2023-03-01 | 2022-12-31 | -1.21 | -1.45 | -0.24 | 19 | ||
2022-11-03 | 2022-09-30 | -1.17 | -1.52 | -0.35 | 29 | ||
2022-08-04 | 2022-06-30 | -1.02 | -0.23 | 0.79 | 77 | ||
2022-05-04 | 2022-03-31 | -0.94 | -1.02 | -0.08 | 8 | ||
2022-02-24 | 2021-12-31 | -0.84 | -0.36 | 0.48 | 57 | ||
2021-11-03 | 2021-09-30 | -0.77 | -0.95 | -0.18 | 23 | ||
2021-08-05 | 2021-06-30 | -0.66 | -0.86 | -0.2 | 30 | ||
2021-05-06 | 2021-03-31 | -0.58 | -0.66 | -0.08 | 13 | ||
2021-02-25 | 2020-12-31 | -0.3 | -0.62 | -0.32 | 106 | ||
2020-11-04 | 2020-09-30 | -0.34 | -0.05 | 0.29 | 85 | ||
2020-08-06 | 2020-06-30 | -0.57 | -0.68 | -0.11 | 19 | ||
2020-05-06 | 2020-03-31 | -0.5 | -0.66 | -0.16 | 32 | ||
2020-03-03 | 2019-12-31 | -0.44 | -0.52 | -0.08 | 18 | ||
2019-10-31 | 2019-09-30 | -0.49 | -0.5 | -0.01 | 2 | ||
2019-08-08 | 2019-06-30 | -0.5 | -0.56 | -0.06 | 12 | ||
2019-05-09 | 2019-03-31 | -0.47 | -0.54 | -0.07 | 14 | ||
2019-02-21 | 2018-12-31 | -0.52 | -0.48 | 0.04 | 7 | ||
2018-11-01 | 2018-09-30 | -0.51 | -0.4 | 0.11 | 21 | ||
2018-07-26 | 2018-06-30 | -0.51 | -0.51 | 0.0 | 0 | ||
2018-04-26 | 2018-03-31 | -0.5 | -0.56 | -0.06 | 12 | ||
2018-02-15 | 2017-12-31 | -0.7 | -0.75 | -0.05 | 7 | ||
2017-10-26 | 2017-09-30 | -0.62 | -0.6 | 0.02 | 3 | ||
2017-08-02 | 2017-06-30 | -0.57 | -0.6 | -0.03 | 5 | ||
2017-04-27 | 2017-03-31 | -0.26 | -0.62 | -0.36 | 138 | ||
2017-02-16 | 2016-12-31 | -0.26 | 0.16 | 0.42 | 161 | ||
2016-10-27 | 2016-09-30 | -0.29 | 0.74 | 1.03 | 355 | ||
2016-07-28 | 2016-06-30 | -0.31 | -0.29 | 0.02 | 6 | ||
2016-04-28 | 2016-03-31 | -0.34 | -0.31 | 0.03 | 8 | ||
2016-02-16 | 2015-12-31 | -0.32 | -0.24 | 0.08 | 25 | ||
2015-10-29 | 2015-09-30 | -0.3 | -0.23 | 0.07 | 23 | ||
2015-07-29 | 2015-06-30 | -0.23 | -0.27 | -0.04 | 17 | ||
2015-04-30 | 2015-03-31 | -0.12 | -0.23 | -0.11 | 91 | ||
2015-02-12 | 2014-12-31 | -0.17 | 0.23 | 0.4 | 235 | ||
2014-10-30 | 2014-09-30 | -0.24 | -0.16 | 0.08 | 33 | ||
2014-07-30 | 2014-06-30 | -0.32 | -0.23 | 0.09 | 28 | ||
2014-05-06 | 2014-03-31 | -0.34 | -0.27 | 0.07 | 20 | ||
2014-02-06 | 2013-12-31 | -0.08 | 0.21 | 0.29 | 362 | ||
2013-10-30 | 2013-09-30 | -0.1 | -0.43 | -0.33 | 330 | ||
2013-07-31 | 2013-06-30 | -0.54 | -0.58 | -0.04 | 7 | ||
2013-04-30 | 2013-03-31 | -0.55 | -0.54 | 0.01 | 1 | ||
2013-02-05 | 2012-12-31 | -0.61 | -0.42 | 0.19 | 31 | ||
2012-10-30 | 2012-09-30 | -0.63 | -0.42 | 0.21 | 33 | ||
2012-07-31 | 2012-06-30 | -0.76 | -0.78 | -0.02 | 2 | ||
2012-04-26 | 2012-03-31 | -0.86 | -0.78 | 0.08 | 9 | ||
2012-02-02 | 2011-12-31 | -1.06 | -0.96 | 0.1 | 9 | ||
2011-10-27 | 2011-09-30 | -1.17 | -0.9 | 0.27 | 23 | ||
2011-07-28 | 2011-06-30 | -0.64 | -1.38 | -0.74 | 115 | ||
2011-04-27 | 2011-03-31 | -1.14 | -1.08 | 0.06 | 5 | ||
2011-02-14 | 2010-12-31 | -1.33 | -1.02 | 0.31 | 23 | ||
2010-10-28 | 2010-09-30 | -1.25 | -1.14 | 0.11 | 8 | ||
2010-07-28 | 2010-06-30 | -1.21 | -1.26 | -0.05 | 4 | ||
2010-04-29 | 2010-03-31 | -1.19 | -1.2 | -0.01 | 0 | ||
2010-02-03 | 2009-12-31 | -1.32 | -1.26 | 0.06 | 4 | ||
2009-10-28 | 2009-09-30 | -1.29 | -0.84 | 0.45 | 34 | ||
2009-07-29 | 2009-06-30 | 3.02 | 5.94 | 2.92 | 96 | ||
2009-04-30 | 2009-03-31 | -1.25 | -1.26 | -0.01 | 0 | ||
2009-02-10 | 2008-12-31 | -2.32 | -1.32 | 1.0 | 43 | ||
2008-10-30 | 2008-09-30 | -2.2 | -1.98 | 0.22 | 10 | ||
2008-07-31 | 2008-06-30 | -1.99 | -1.86 | 0.13 | 6 | ||
2008-04-29 | 2008-03-31 | -1.9 | -1.68 | 0.22 | 11 | ||
2008-01-31 | 2007-12-31 | -2.43 | -1.62 | 0.81 | 33 | ||
2007-10-31 | 2007-09-30 | -2.35 | -1.44 | 0.91 | 38 | ||
2007-07-31 | 2007-06-30 | -2.17 | -1.62 | 0.55 | 25 | ||
2007-04-26 | 2007-03-31 | -2.41 | -1.5 | 0.91 | 37 | ||
2007-01-31 | 2006-12-31 | -3.49 | -2.46 | 1.03 | 29 | ||
2006-10-26 | 2006-09-30 | -3.01 | -2.46 | 0.55 | 18 | ||
2006-07-27 | 2006-06-30 | -2.89 | -2.22 | 0.67 | 23 | ||
2006-04-27 | 2006-03-31 | -2.91 | -2.16 | 0.75 | 25 | ||
2006-01-31 | 2005-12-31 | -2.83 | -2.28 | 0.55 | 19 | ||
2005-10-26 | 2005-09-30 | -2.44 | -2.1 | 0.34 | 13 | ||
2005-07-27 | 2005-06-30 | -2.74 | -2.22 | 0.52 | 18 | ||
2005-04-27 | 2005-03-31 | -2.68 | -2.22 | 0.46 | 17 | ||
2005-02-03 | 2004-12-31 | -2.36 | -2.52 | -0.16 | 6 | ||
2004-10-21 | 2004-09-30 | -2.88 | -2.16 | 0.72 | 25 |
Cytokinetics Corporate Management
| John Esq | Associate VP | Profile | |
| Andrew Callos | Executive Officer | Profile | |
| Jeff Lotz | Vice Operations | Profile | |
| Steven Cook | Senior Operations | Profile | |
| Scott Jordan | Senior Strategy | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.26) | Revenue Per Share | Quarterly Revenue Growth 9.124 | Return On Assets | Return On Equity |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.